Pre-clinical work has found that tumor cell IL1β drives TAM recruitment, immunosuppression, and tumor progression in TNBC (Shen et al., 2017; Jaiswal et al., 2021) (Figure 1). This evidence concerns the gene IL1B and neoplasm.